ARS Pharmaceuticals (SPRY) Cash & Equivalents (2020 - 2026)

ARS Pharmaceuticals has reported Cash & Equivalents for 7 years, with the latest figure at $24.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 38.99% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (down 38.99% YoY) and the FY2025 annual result came in at $41.3 million, down 18.69% from the prior year.
• Cash & Equivalents eased to $24.3 million in Q1 2026 per SPRY's latest filing, from $41.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $234.0 million in Q1 2022 and troughed at $24.3 million in Q1 2026.
• A 5-year average of $94.4 million and a median of $59.6 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 250.5% in 2022, then sank 70.21% in 2023.
• Over 5 years, Cash & Equivalents stood at $210.5 million in 2022, then plunged by 66.29% to $71.0 million in 2023, then decreased by 28.4% to $50.8 million in 2024, then fell by 18.69% to $41.3 million in 2025, then slumped by 41.14% to $24.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $24.3 million, $41.3 million, and $59.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.